Long-term algorithmic price predictions for Akebia Therapeutics (AKBA) extending out to the year 2030 project a wide trading range as the company matures within the commercial biopharmaceutical space. Quantitative forecasting models suggest that by 2030, the stock could experience periods where minimum projected values hover around 1.00 to 1.30 USD, while optimistic peak estimates or average year-end targets may scale higher depending on the long-term sales trajectory of Vafseo and potential pipeline expansions. Because forecasting micro-cap and small-cap biotechnology stocks several years into the future involves substantial uncertainty regarding clinical success and market competition, these long-term models serve primarily as speculative scenarios rather than guaranteed financial outcomes.